pharmaphorum January 13, 2025
Last week’s rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money.
This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, with another $150 million in payments to the biotech’s shareholders if its pipeline delivered as expected.
The deal coincides with the start of the JP Morgan healthcare conference in San Francisco, which has become a popular venue for announcing M&A and other deals at the beginning of each year.
That pipeline is led by IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) that is being developed as a...
Today's Sponsors
Today's Sponsor